Clarity Pharmaceuticals Announces US FDA Grants Cu-67 SARTATE™ Orphan Drug Designation for Neuroblastoma
Sydney, Australia 21 April 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for 67Cu-SARTATE™, a therapy for the clinical management of neuroblastoma. Neuroblastoma most often occurs in children younger than 5…